$26.6 Bn Cancer Diagnostics Markets, 2026 – Growing Focus on Personalized Medicine / Companion Diagnostics / Recommendations for Cancer Screening – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cancer Diagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals) – Global Forecasts to 2026” report has been added to ResearchAndMarkets.com’s offering.

The global cancer diagnostics market size is projected to reach USD 26.6 billion by 2026 from USD 17.2 billion in 2021, at a CAGR of 11.5% from 2021 to 2026.

Growth in this market is driven by the rising prevalence of cancer, and growing initiatives undertaken by government bodies to create awareness about cancer, the increasing number of private diagnostic centers.

Consumables segment to witness the highest growth during the forecast period.

Based on the product, the cancer diagnostics market is segmented into consumables and instruments. The consumables segment is projected to grow at the highest CAGR during the forecast period. high prevalence of cancer, number of reagent rental agreements, and the growing application of innovative technologies and methodologies are the major factor supporting the growth of this segment.

Breast cancer segment to register the highest growth in the cancer diagnostics market during the forecast period.

Based on the application, the cancer diagnostics market is segmented into breast cancer, lung cancer, colorectal cancer, melanoma, and other cancer. The breast cancer segment is projected to witness the highest growth in the cancer diagnostics market during the forecast period. The increasing incidence of cancer and technological advancement are the major factors supporting the growth of this segment.

Asia Pacific is estimated to register the highest CAGR during the forecast period.

In this report, the cancer diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in the Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by The increasing incidence of cancer, the increasing number of patients visiting hospitals, and growing awareness regarding early diagnosis.

List of Companies Profiled in the Report

• Abbott Laboratories (US)
• Agilent Technologies Inc.(US)
• AMOY Diagnostics CO. LTD. (China)
• BD (US)
• Bio SB (US)
• Bio-Rad Laboratories (US)
• Biocartis NV (Belgium)
• bioMerieux SA (France)
• Cancer Diagnostics Inc. (US)
• Danaher Corporation (US)
• DiaSorin S.P.A. (Italy)
• Exact Science (US)
• FUJIFILM Corporation (Japan)
• GE Healthcare (US)
• Hologic Inc. (US)
• Myriad Genetics Inc. (US)
• Quidel Corporation (US)
• Roche Diagnostics (Switzerland)
• Siemens Healthineers AG (Germany)
• Vela Diagnostics (Singapore)

For more information about this report visit https://www.researchandmarkets.com/r/a34ry4

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900